All News

Early detection and treatment of lung cancer through screening with low-dose computed tomography (CT) has been investigated as a potential tool for reducing lung cancer deaths, the leading cause of cancer death worldwide, for more than 2 decades. Published this week was an extended follow up study to the 2011 randomized National Lung Screening Trial that found a similar number of patients must be screened to prevent cancer deaths as determined in the original analysis.

In a session held during the Florida Society of Clinical Oncology’s annual meeting in April, panelist James Almas, MD, vice president and national medical director of clinical effectiveness at LabCorp, and previously a medical officer at CMS in the Coverage Analysis Group, announced that he expected the National Coverage Determination to be reopened for Foundation Medicine’s FDA-approved companion diagnostic. By the end of the month, CMS revealed that they had done just that.

Impulsive and compulsive behaviors have become increasingly associated with Parkinson disease (PD) and treatment. Recently, the International Parkinson’s and Movement Disorder Society commissioned a task force to assess currently available screening tools and rating scales in order to make recommendations regarding their utility, as well as to inform future directions in scale development and validation.

Achieving undetectable minimal residual disease (MRD) status is important for deep and durable responses in patients with chronic lymphocytic leukemia (CLL), according to 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting.

While minimal residual disease (MRD) is being used to assess response to treatment in multiple myeloma (MM), the level of risk a patient has can make a big different in how well MRD works as a prognostic indicator, according to 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting.

This week, the top managed care news included President Trump issuing an executive order for more healthcare transparency; provisional data indicating that overdose deaths may be falling; the Supreme Court agreeing to hear insurers' Affordable Care Act lawsuit.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text